As we elucidate cancer biology, it has become increasingly clear that growth factor or cytokine receptors and/or their intracellular second messengers can provide attractive new targets for novel cancer therapeutics. Indeed, a vast new array of small molecule inhibitors that target growth factor or cytokine receptors and/or their intracellular signalling pathways are in pre-clinical and clinical development. Understanding the target biology, how these agents act and how they will integrate into clinical practice is vital for both scientists and clinicians working in translational cancer research. Consequently, this meeting will bring together scientists and clinicians who are either working on or are interested in learning about cell signalling in cancer therapeutics. Key speakers from across North America and Europe who work in both university and pharmaceutical backgrounds will provide the latest information in this hot area of new science. Our two day international meeting will have sessions focused on receptors, mTOR / S6 kinase, BRaf/MEK/Erk, JAK/STAT, PI3K/apoptosis and Src/migration signalling. Each session will have a biology component followed by a clinical translation talk. Students, post-doctoral fellows and research clinicians are encouraged to submit abstracts which will be selected for either oral or poster sessions with a prize awarded for the best oral and poster presentations.

Registration required:

Yes

Free:

No